This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Biochemical Assays Remove Fragment Screening Remove Treatment
article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. In terms of compound libraries, we have a high-throughput screening library of about 200,000 ligands. We can screen with many different formats and modalities.

Fragment Screening 96
Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96
article thumbnail

SARS-CoV-2 main protease. Crowdsourcing, peptidomimetics and fragments

Molecular Design

JULY 18, 2020

While I’m not particularly keen on the use of the term ‘open source’ in this context, I have absolutely no quibble with the goal of seeking cures and treatments for diseases that are ignored by commercial drug discovery organizations.

Biochemical Assays 52
Biochemical Assays Fragment Screening Pharmacokinetics Drugs 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024